Call Us: +31 (0) 73 - 627 4520 - Mail info@immunovo.com

Product portfolio

image009

Sclerostin

Product

A therapeutic vaccine against the bone remodeling protein sclerostin (SCLER). This protein is thought to interfere with canonical Wnt/&A therapeutic vaccine against the bone remodeling protein sclerostin (SCLER). This protein...

View Details
image010

PD1

Product

Immune recognition and elimination of malignant cells require a series of steps orchestrated by the innate and the adaptive arms of the immune system. The majority of tumors have evolved...

View Details
image004

PEPA10/RFASE Immunebooster

Product

Safe And Effective Adjuvants: The Missing Link In addition to synthetic peptide technology, the immune response against relatively weak ‘self’ antigens requires maximization to obtain the desired effect in all...

View Details
image012

Gastrine

Product

Patients with pancreatic cancer usually present with advanced disease and have a poor prognosis. ImmuNovo’s approach is to develop a therapeutic vaccine, based on gastrin, that will lead to the...

View Details
Poster-AACR-2015_08-04-2015

VEGF

Product

Immunovo’s Immune Activation System “IAS” A Novel Approach to Angiogenesis Inhibition Immunotherapy as a treatment modality in oncology has recently gained solid ground with the use of monoclonal antibodies (MAbs)...

View Details
image006

GnRH

Product

Therapeutic vaccines are directed against ‘self’ proteins. ‘Self’ proteins as such make poor immunogens and often do not induce antibodies at all. ImmuNovo has found ways around this obstacle. Therapeutic...

View Details
Back to Top